ClinicalTrials.gg
CompletedNCT01496742Updated Sep 23, 2016

A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer

A Phase 2 interventional study of Placebo and RO5490258 in Non-Squamous Non-Small Cell Lung Cancer, sponsored by Genentech, Inc.. Completed at 87 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-09-23.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
259
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 150 studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung — 9 open to participants now, 15 under way, 3 of them phase 3. Bevacizumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
30th of 149
259 · median 56
Started
2012
with 5 others
Phase 2
95 of 150
6 open now
Registered
83rd of 150
by date
Lead sponsor
6 of 150
Genentech, Inc.

Among the 150 studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung, this one is the 30th largest by enrollment of the 149 interventional ones that give a count, is one of 6 that started in 2012, is one of 95 in phase 2, and was the 83rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

9 of the 150 studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung are open now, in 3 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 150 studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of RO5490258 (MetMab) in combination with either of two backbone chemotherapy regimens in the first-line setting in patients with incurable Stage IIIB or IV non-squamous non-small cell lung cancer. In Cohort 1, patients will be randomized to receive 4 cycles of bevacizumab (Avastin) 15 mg/kg iv, paclitaxel 200 mg/m2 iv, platinum (cisplatin/carboplatin) iv plus either MetMab 15 mg/kg iv or placebo on Day 1 of each 21-day cycle. In Cohort 2, patients will be randomized to receive pemetrexed 500 mg/m2 iv, platinum (cisplatin/carboplatin) iv plus either MetMAb 15 mg/m2 iv or placebo on Day 1 of each 21-day cycle. Patients who have not progressed after 4 cycles will be offered maintenance therapy with their assigned treatment of bevacizumab plus either MetMAb or placebo (Cohort 1) or pemetrexed plus either MetMAb or placebo (Cohort 2). Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.

03

Conditions studied

  • Non-Squamous Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, >/= 18 years of age
  • or cytologically confirmed Stage IIIB or Stage IV non-squamous non-small cell lung cancer (NSCLC)
  • (ECOG) performance status 0 or 1
  • For patients who received prior chemotherapy or chemoradiotherapy: a treatment-free interval of at least 12 months since last chemotherapy or chemoradiotherapy cycle
  • Adequate tissue for central immunohistochemical (IHC) assay of Met receptor, and epidermal growth factor receptor (EGFR) testing if EGFR status is unknown
  • Radiographic evidence of disease

Exclusion criteria

Exclusion Criteria:

  • Prior systemic treatment for Stage IIIB or IV non-squamous NSCLC
  • Evidence of mixed NSCLC with a predominance of the squamous cell type
  • Prior exposure to experimental treatment targeting either the hepatocyte growth factor (HGF) or Met pathway
  • Patients with tumors confirmed to have EGFR-activating mutations who are suitable for anti-EGFR therapy (e.g. gefitinib or erlotinib), as determined by the investigator, unless that treatment is unavailable or refused by the patient
  • Known central nervous system (CNS) disease, other than stable, treated
  • History of another in the previous 3 years, except for history of in situ cancer that was treated surgically with curative intent, localized prostate cancer that has been treated surgically with curative intent, or basal or squamous cell skin cancer
  • Uncontrolled diabetes
  • Pregnant or lactating women
  • Impaired bone marrow, liver or renal function (as defined by protocol)
  • Significant history of cardiovascular disease
  • Positive for infection
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
259 participants (actual)

Study arms

  • Experimental
    Bevacizumab+MetMAb

    Drug: RO5490258 · Drug: bevacizumab [Avastin] · Drug: cisplatin/carboplatin · Drug: paclitaxel

  • Active comparator
    Bevacizumab+Placebo

    Drug: Placebo · Drug: bevacizumab [Avastin] · Drug: cisplatin/carboplatin · Drug: paclitaxel

  • Experimental
    Pemetrexed+MetMAb

    Drug: RO5490258 · Drug: cisplatin/carboplatin · Drug: pemetrexed

  • Active comparator
    Pemetrexed+Placebo

    Drug: Placebo · Drug: cisplatin/carboplatin · Drug: pemetrexed

Interventions

  • DrugPlacebo

    Matching RO5490258 (MetMAb) placebo iv, Day 1 of each 21-day cycle

  • 15 mg/kg iv, Day 1 of each 21-day cycle

    Also known as: MetMAb

  • 15 mg/kg iv, Day 1 of each 21-day cycle

  • Drugcisplatin/carboplatin

    Drug pages: Cisplatin · Carboplatin

    standard dose iv, Day 1 of each 21-day cycle, 4 cycles

  • 200 mg/m2 iv, Day 1 of each 21-day cycle, 4 cycles

  • 500 mg/m2, Day 1 of each 21-day cycle

06

What researchers measure

Primary outcomes

  1. Progression-free survival (tumor assessments according to RECIST criteria)

    Time frame: up to approximately 23 months

  2. Progression-free survival: Subgroup of patients with Met diagnostic positive tumors

    Time frame: up to approximately 23 months

Secondary outcomes

  1. Overall survival

    Time frame: up to approximately 23 months

  2. Overall response rate (tumor assessments according to RECIST criteria)

    Time frame: up to approximately 23 months

  3. Duration of response (time from first documented objective response to disease progression)

    Time frame: up to approximately 23 months

  4. Disease control rate (rate of partial response plus complete response plus stable disease for at least 6 weeks)

    Time frame: up to approximately 23 months

  5. Safety: Incidence of adverse events

    Time frame: up to approximately 23 months

  6. Pharmacokinetics: serum concentration (Cmin/Cmax)

    Time frame: Pre- and post-dose on Day 1 of Cycles 1, 2 and 4 and at study termination

  7. Serum concentrations of bevacizumab/paclitaxel/pemetrexed/platinum in combination with MetMAb

    Time frame: Pre- and post-dose on Day 1 of Cycles 1 and 4

  8. Serum levels of anti-therapeutic antibodies (MetMAb ATAs)

    Time frame: Pre-dose Day 1 of Cycles 1, 2 and 4

07

Study locations

87 sites
  • Huntsville, Alabama 35805, United States
  • Scottsdale, Arizona 85259, United States
  • Bakersfield, California 93309, United States
  • Fullerton, California 92835, United States
  • Los Angeles, California 90024, United States
  • Los Angeles, California 90095-1772, United States
  • Northridge, California 91328, United States
  • San Luis Obispo, California 93454, United States
  • Santa Barbara, California 93105, United States
  • Stanford, California 94305-5820, United States
  • Grand Junction, Colorado 81502-1628, United States
  • Boynton Beach, Florida 33435, United States
  • Hollywood, Florida 33021, United States
  • Orlando, Florida 32804, United States
  • Lawrenceville, Georgia 30045, United States
  • Marietta, Georgia 30060, United States
  • Harvey, Illinois 60426, United States
  • Fort Wayne, Indiana 46815, United States
  • Fort Wayne, Indiana 46845, United States
  • Indianapolis, Indiana 46260, United States
  • Muncie, Indiana 47303, United States
  • Metairie, Louisiana 70006, United States
  • Minneapolis, Minnesota 55454, United States
  • Las Vegas, Nevada 89148, United States
  • New York, New York 10016, United States
  • Hickory, North Carolina 28602, United States
  • Cleveland, Ohio 44195, United States
  • Columbus, Ohio 43215, United States
  • Middletown, Ohio 45042, United States
  • Bend, Oregon 97701, United States
  • Portland, Oregon 97239, United States
  • Seattle, Washington 98195, United States
  • Buenos Aires, C1426ANZ, Argentina
  • La Rioja, F5300COE, Argentina
  • Santa Rosa, L6304BOC, Argentina
  • Grenoble, 38043, France
  • Paris, 75230, France
  • Paris, 75674, France
  • Rennes, 35033, France
  • Göttingen, 37075, Germany
  • Halle (Saale), 06120, Germany
  • Immenhausen, 34376, Germany
  • München, 81925, Germany
  • Münster, 48149, Germany
  • Afula, 18101, Israel
  • Ashkelon, 78278, Israel
  • Holon, 58100, Israel
  • Tel Aviv, 6423906, Israel
  • Zerifin, 6093000, Israel
  • Avellino, Campania 83100, Italy
  • Udine, Friuli-Venezia Giulia 33100, Italy
  • Roma, Lazio 00149, Italy
  • Cremona, Lombardia 26100, Italy
  • Milano, Lombardia 20133, Italy
  • Orbassano, Piemonte 10043, Italy
  • Daugavpils, 5417, Latvia
  • Liepaja, LV 3401, Latvia
  • Riga, LV 1079, Latvia
  • Riga, LV-1002, Latvia
  • Kuala Lumpur, 56000, Malaysia
  • Negeri Sembilan, 71800, Malaysia
  • Penang, 10050, Malaysia
  • Pulau Pinang, 11600, Malaysia
  • Tanjung Bungah, 11200, Malaysia
  • Aguascalientes, 20234, Mexico
  • Chihuahua, 31000, Mexico
  • Leon, 37150, Mexico
  • CEBU City, 6000, Philippines
  • Davao City, 8000, Philippines
  • Pasig City, 1605, Philippines
  • Quezon City, 1104, Philippines
  • Quezon City, 1114, Philippines
  • Pamplona, Navarra 31008, Spain
  • Barcelona, 08036, Spain
  • Madrid, 28007, Spain
  • Madrid, 28050, Spain
  • Zaragoza, 50009, Spain
  • Kaohsiung, 807, Taiwan
  • Taichung, 40705, Taiwan
  • Tainan, 704, Taiwan
  • Taipei, 00112, Taiwan
  • Taipei, 100, Taiwan
  • Aberdeen, AB25 2ZN, United Kingdom
  • Birmingham, B9 5SS, United Kingdom
  • Bournemouth, BH7 7DW, United Kingdom
  • Leeds, LS9 7TF, United Kingdom
  • Manchester, M23 9QZ, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2011
First posted
Dec 21, 2011
Start
Apr 2012
Primary completionActual
Nov 2015
CompletionActual
Nov 2015
Last update
Sep 23, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01496742
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Dec 21, 2011
Start date
Apr 2012
Primary completion
Nov 2015
Completion
Nov 2015
Last update
Sep 23, 2016

Study contacts

Clinical Trials
study director · Genentech, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Onartuzumab · Bevacizumab · Paclitaxel · Pemetrexed

Start the discussion